Background: Despite rising antimicrobial resistance, treatment guidelines for chronic
Introduction
The rising prevalence of antimicrobial resistance due to uncontrolled antimicrobial use has been recognised as an urgent global health priority. 1 Infections with resistant bacteria are associated with prolonged hospitalisations and increased medical investigations, financial costs, mortality and morbidity. 2 Chronic obstructive pulmonary disease (COPD) is characterised by persistent symptoms, fixed airflow obstruction, parenchymal lung destruction and a variable number of exacerbations. 3 A COPD exacerbation may be caused by an infectious or non-infectious precipitant. While 50% of patients will culture a bacterial organism during an exacerbation, not all bacteria are pathogenic; 30% of stable COPD patients culture bacterial organisms when well, and thus are colonised. 4 Australian COPD Guidelines 5, 6 recommend that, in the absence of radiographic pneumonia, antimicrobial therapy (i.e. oral amoxycillin or doxycycline for 5-7 days duration) should be reserved for patients presenting with a significant change in symptoms suggesting an acute infection. The presence of two or more 'cardinal symptoms' of increased dyspnoea, sputum volume and sputum purulence has been shown to predict the presence of bacteria in sputum and therefore which patients may respond to antimicrobial therapy to treat the exacerbation, in addition to bronchodilators and glucocorticoids. 7, 8 A summary of national guidelines for the antimicrobial treatment of COPD exacerbations (without radiological evidence of pneumonia) and communityacquired pneumonia is provided in Table 1 . However, adherence to guidelines by general practitioners and hospital specialists appears to be poor, as nearly 90% of patients who experience an acute exacerbation of COPD in both settings are prescribed antimicrobials and up to 85% of agents are prescribed to patients who do not report a significant change in cardinal symptoms. [9] [10] [11] In addition, guideline recommendations regarding the route and number of antimicrobials are frequently disregarded: half of all inpatients receive at least two antimicrobials and 45% receive intravenous therapy.
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Infections are common at the end of life. Nearly half of patients with advanced dementia, 90% of hospitalised patients with end-stage cancer and over a quarter of patients in hospices are commenced on antimicrobials in the final 2 weeks of life. [12] [13] [14] Despite the documented goal of care being to optimise symptom palliation and reduce burdensome interventions or treatments, antimicrobials are continued into the terminal phase (last few days of life) in more than one-third of cancer patients. 12 As almost three-quarters of Australian COPD patients die in hospital, 15 we hypothesised that these patients may receive more antimicrobials in a bid to preserve life, compared with those patients who survive exacerbations. Accordingly, this study aimed to examine antimicrobial prescription in patients who died in a tertiary hospital from an exacerbation of COPD.
Methods
A retrospective medical record audit was performed of 475 consecutive patients who died at The Royal Melbourne Hospital (Australia) over 12 years between 1 January 2004 and 31 December 2015, with COPD listed as one of the first five diagnoses at death. The cohort was limited to include only patients with a confirmed diagnosis of COPD (by spirometry or radiological investigations) and who died as a consequence of COPD and not from comorbidities, such as cancer or heart failure.
Patients with emphysema or COPD (International Classification of Diseases (ICD) codes J43-44) listed in diagnosis 1-5 were identified from the hospital mortality database. Patients with a diagnosis of asthma (ICD code J45) were included in the initial search to ensure no deaths were misattributed to asthma. On reviewing the medical files, all asthma deaths were excluded.
Paper clinical records and electronic, administrative and clinical databases (including pathology and radiology databases) were examined to determine the use and duration of therapeutic treatments, including antimicrobials during the final admission in which death occurred. Data collected included demographic information and pre-admission disease severity (lung function testing, use of domiciliary oxygen and inferred modified Medical Research Council breathlessness score). While all patients had obstruction confirmed on spirometry, only lung function tests results performed within 2 years prior to death were included.
Information regarding the duration of admission, presence of cardinal symptoms on presentation (for patients without radiological evidence of pneumonia), inflammatory markers on admission including white cell count (WCC) and C-reactive protein (CRP), microbiology, radiology results and antimicrobial use were also collected. Single-dose antimicrobial(s) given in the emergency department (ED) was(were) excluded.
Included patients were divided into three groups. Group 1 consisted of patients with pneumonia, based on 
Statistical analysis
Patient demographics are reported descriptively using counts and frequencies. Median values are reported for variables with significant distribution skew. Student's paired t-test was used to compare means from continuous variables. Categorical variables were compared using the Chi-squared test or Fisher's exact test when indicated, with univariate logistic regression used to explore positive associations further. Statistical analyses were performed using IBM SPSS Statistics version 24 (Armonk, NY, USA), with a P-value of less than 0.05 indicating statistical significance.
Results

Patient characteristics
Of 475 patients, 221 who died from COPD were included; 240 died primarily from a cause other than COPD and 14 had missing medical files. On admission, 72 (32.6%) patients had pneumonia (Group 1), 117 (52.9%) had an infective exacerbation of COPD (Group 2) and 32 (14.5%) had a non-infective exacerbation of COPD. Based on calculated admission CURB-65 scores, 17 70 patients in Group 1 had severe pneumonia, and 2 patients had moderate (non-severe) pneumonia.
The study population was elderly, with mean age of 80 years, and patients had severe breathlessness and severe lung function impairment at baseline (Table 2) . Patients with pneumonia (Group 1) had significantly fewer admissions to hospital in the previous year compared to patients who were admitted with a noninfective exacerbation of COPD (Group 3, P = 0.002)
Approximately two-thirds (n = 134, 60.6%) of patients were admitted under a general medical unit, one-quarter (n = 61, 27.6%) admitted under respiratory medicine and the remainder under other medical units, including nine (4.1%) patients admitted directly under palliative care. There was a non-significant trend to more patients in Group 1 (8.3%) being intubated compared to Group 2 (1.7%) and Group 3 (1.7%). Over half of all patients (54.8%) received acute non-invasive ventilation (NIV) during admission, with similar rates of NIV use across the three groups.
On admission, 61 (52.1%) Group 2 patients had two or more cardinal symptoms consistent with an infection exacerbation, compared to none of the patients in Group 3 (P < 0.0001). Group 2 patients commonly reported increased sputum purulence (n = 48, 41.0%) or increased sputum volume (n = 59, 50.4%); however, none of the Group 3 patients reported either symptom (P < 0.001). Patients in both groups reported increased dyspnoea on admission, although rates were higher in Group 2 than Group 3 (80.3% vs 53.1%, P = 0.0029).
Sputum culture results
Pathogenic bacteria were cultured in the sputum of 75 (33.9%) patients, with this occurring significantly more frequently in Group 2 patients (P = 0.0072) compared with Group 3 (Table 3) . Commonly cultured bacteria included Pseudomonas aeruginosa, Moraxella catarrhalis, Haemophilus influenzae and Stenotrophomonas maltophilia. While resistance to first-line antimicrobial therapy was present in one-third of organisms (25 patients), antimicrobial therapy was changed because of resistance in only nine (4.1%) patients.
Antimicrobial therapy
Antimicrobials were prescribed to 200 (90.5%) patients (Table 4) , with the prescription frequency being similar in Group 1 (94.4%) and Group 2 (92.3%), but significantly lower for Group 3 patients (75.0%, P = 0.011).
The majority (176, 79.6%) of patients across all groups received intravenous antimicrobial therapy. However, this occurred more frequently in Group 1 patients (90.3%) compared to Group 2 (77.8%, P = 0.031) or Group 3 (62.5%, P = 0.002).
Prescribed antimicrobial therapy was concordant with guidelines in approximately one-third (n = 70, 31.7%) of patients; however, significantly fewer patients in Group 2 (4.2%, P < 0.0001) and Group 3 (25.0%, P = 0.0002) received guideline-concordant therapy compared with Group 1 (79.2%).
Of the 151 (68.3%) patients who received discordant antimicrobial therapy, the reasons included: intravenous route when oral indicated (n = 111, 73.5%), oral route when intravenous indicated (n = 2, 1.3%), dual therapy when monotherapy recommended (n = 108, 77.1%), no symptoms of acute infection (n = 24, 17.1%), nonguideline oral antimicrobial (13, 8 .6%), non-guideline intravenous antimicrobial (10, 6.6%) and no antimicrobial prescribed when antimicrobials were indicated (n = 15, 9.9%). Ceftriaxone was the most frequently prescribed antimicrobial, in 60.2% of the cohort, and nearly half (n = 99, 44.8%) of the patients received azithromycin (Table 4) . Thirty (13.6%) patients received agents with activity against Pseudomonas aeruginosa, although only six patients had cultured this organism in the 12 months prior to their final admission. Of patients in Groups 2 and 3, only 12 (8.1%) patients were referred to specialist palliative care services prior to their terminal hospital admission. These patients were more likely to receive guideline-concordant therapy (P = 0.016, odds ratio (OR) 5.2, 95% confidence interval (CI) = 1.4-20.0) compared with the rest of the cohort. Patients who required NIV or intubation were more likely to receive discordant antimicrobial treatment (P = 0.020, OR 3.8, 95% CI = 1.2-11.5).
No significant associations were found between discordant antimicrobial therapy and any other patient, disease or admission characteristics (age, preadmission functional status, lung function impairment, admission WCC, CRP, ABG pH or PaCO 2 , admitting team, inpatient involvement of palliative care unit, inpatient consultation by respiratory medicine sputum culture organism or significant antimicrobial resistance in sputum).
Duration and withdrawal of antimicrobials
The median duration of antimicrobial use was 4 days (interquartile range 2-8 days), and 53 patients (24.0%) received antimicrobials for longer than 7 days. Antimicrobials were withdrawn prior to death in 140 patients, leaving 60 (27.1%) patients who died while receiving antimicrobials. Thirty-four (15.4%) patients continued to receive antimicrobials at the time of death despite having a goal of care to provide comfort only.
Healthcare costs
The cost of individual antimicrobials ranged widely, from $0.24 per day for oral doxycycline to $39.90 per day for intravenous azithromycin. The cost of prescribed antimicrobials in patients who received guideline-discordant therapy totalled $11 780. Azithromycin, benzylpenicillin and moxifloxacin accounted for 59.3%, 11.1% and 9.6% of total cost respectively.
Discussion
In this novel study of antimicrobial use in patients who die from COPD exacerbations, most patients received discordant antimicrobial therapy, with the highest rates seen in patients who did not have radiological evidence of pneumonia or symptoms suggesting acute infection. Whilst antimicrobials were ceased prior to death in the majority of cases, over one-quarter of patients continued to receive antimicrobials at the time of death.
Patients presenting with COPD exacerbations present several clinical challenges. Breathlessness frequently occurs in stable disease, during COPD exacerbations and from other causes and is therefore not helpful alone in determining significant changes in disease state. 18 As infection is the most treatable cause for breathlessness and antimicrobials may be lifesaving, perhaps it is not surprising that many patients continue to receive antimicrobials in the absence of clinical, pathological or radiological evidence of infection. In addition, the course of COPD exacerbations is difficult to predict: while respiratory failure is the most common cause of mortality in COPD 19 and up to 10% of patients with hypercapnic respiratory failure will die during their admission, 20 many patients seemingly in extremis will have a rapid clinical response to treatments such as NIV. Unfortunately, clinicians have been shown to be poor discriminators of the outcomes of COPD exacerbations. 21 Challenges in determining the aetiology and clinical course of a COPD exacerbation may go some way to explain the low rates of compliance with antimicrobial guidelines documented in previous studies.
9-11 Fanning et al. showed that, in a cohort of Australian inpatients who survived an exacerbation of COPD, the rate of discordant antimicrobial prescription was 87.5%. Similarly, in our study of patients who died from COPD and who did not have pneumonia, discordant prescription occurred in 91.3% of cases. Variation in the baseline functional status and the severity of exacerbations may explain the minor difference in results; we note that our cohort, was older and had higher rates of home 02 prescription, lower FEV1 results and required NIV treatment more frequently. Tools are available to assist clinicians in discriminating patients who are likely to survive admission from those likely to deteriorate. The Dyspnoea, Eosinopenia, Consolidation, Acidaemia and Atrial Fibrillation (DECAF) score is a simple-to-perform, validated predictor of in-hospital mortality in COPD exacerbations, superior to other prognostic tools, such as CURB-65, and equivalent to the APACHE II score. 22 The median time to death in patients with the highest DECAF scores (5 or 6 out of 6) is 2 days. The use of validated mortality prediction tools, such as DECAF may facilitate the early implementation of palliative treatments and the review of antimicrobials in patients with high scores on admission.
As less than one-third of COPD exacerbations are caused by bacteria, 4 clinicians must remain vigilant regarding appropriate antimicrobial prescription as there is potential to cause harm by excessive antimicrobial use. Adverse events related to antimicrobial use occur in 20% of patients, 23 and unnecessary antimicrobial prescription contributes to the increasing rates of antimicrobial resistance. Current data from Australian hospitals 24 show that, while penicillin-resistant Streptococcus pneumoniae remains rare, resistance in Enterobacteriaceae (including Klebsiella pneumoniae and H. influenzae) through acquired B-lactamase production is now present in at least half of human-isolated strains. In public hospitals, resistance to piperacillin-tazobactam is present in over 10% of P. aeruginosa isolates, with similar rates seen for other first-line agents. The rates of resistance in S. pneumoniae and Enterobacteriaceae in our cohort (0% and 50% respectively) are consistent with contemporary data, while as many as 57% of P. aeruginosa isolates in our study demonstrated resistance to first-line antimicrobials. This should be of particular worry to clinicians given that multidrug-resistant P. aeruginosa quadruples inpatient mortality, 25 and cross-transmission of resistant P. aeruginosa serotypes has been documented between patients in tertiary hospitals. 26 We found that ceftriaxone-based antimicrobial regimens were employed most frequently, in over twothirds of patients with pneumonia and over half of patients with infective exacerbations of COPD. In the prospective, multicentre Australian Community Acquired Pneumonia Study, 27 in which 25% of patients had COPD, penicillin-based regimens were more common than ceftriaxone-based regimens (56% vs 37% respectively), with ceftriaxone more commonly used in patients with severe pneumonia. In the single-centre study by Fanning et al., 43% received penicillin-or ampicillin-based regimens, and only 13% received ceftriaxone. However, we note that the mortality rate was significantly lower in both these studies (5.6% and 0% respectively).
The higher rate of ceftriaxone use in our study may be due in part to the increased severity of clinical presentation, including much higher rates of NIV usage. Patients in our cohort requiring NIV were more likely to receive discordant antimicrobial therapy, and while a Cochrane review 28 has shown that antimicrobials may reduce mortality and length of hospital stay in patients suffering from COPD exacerbations requiring intensive care, this recommendation has not been upheld in local guidelines. 5, 6 While reduced consciousness may influence the route of antimicrobial treatment in some patients, only three patients in our study required intubation. In addition, antimicrobial allergies may have affected prescription; however, this is unlikely to have significantly affected our results as the incidence of dual allergy to penicillin and tetracycline is extremely low. 29 It is likely that the choice of antimicrobials used on the ward was also influenced by the initial antimicrobial used in the ED. Kiyatkin et al. showed that, in patients treated for a urinary tract infection in the ED, over half were treated with inappropriate antimicrobials, the majority of which were continued into the admission. 30 We hypothesise that a similar effect may occur in treating COPD exacerbations: antimicrobials are frequently initiated by junior medical staff in the ED who may not have a full understanding of current guidelines. Lack of awareness and familiarity with clinical practice guidelines have been repeatedly shown to be the principal barrier to guideline adherence. 31 In addition to promoting guideline awareness, a regular review of the rationale for antimicrobial choice should occur for all patients throughout their admissions to ensure that the most appropriate antimicrobial therapy is prescribed.
A systematic review demonstrated that respiratory physicians were more likely to adhere to guidelines when managing hospitalised patients with COPD exacerbations. 32 While we found no difference in the rates of discordant antimicrobial therapy according to treating team, the low numbers of patients admitted to the Respiratory Unit may have influenced our results. In addition, we found no difference in antimicrobial guideline adherence for patients for whom an opinion regarding the use of NIV was sought from the respiratory team. Therefore, perhaps respiratory consultations are an underused opportunity, during which the appropriateness of the antimicrobial therapy regimen could also be reviewed.
Focusing on active treatments may distract clinicians from recognising that a patient is dying despite best efforts and requires good symptom palliation and comfort care. While most antimicrobials were ceased appropriately, a quarter of our cohort continued to receive antimicrobials at the time of death. Although clinicians may have failed to recognise imminent death, other factors may have contributed such as a rapid deterioration in patient condition or due to the wishes of the patient's family.
Limitations
This was a single-centre, retrospective, medical record audit, in which data collection was dependent on the quality of documentation in medical notes. Similarly, due to poor medical record documentation, it was not possible to collect accurate data regarding oral antimicrobials use prior to hospital admission. The latter may have influenced the choice of antimicrobials used in hospital and warrants further study.
Conclusion
Antimicrobial prescription in patients who die from COPD exacerbations deviates widely from current guidelines, with antimicrobials being both overprescribed and non-guideline antimicrobials being overused. Therefore, greater antimicrobial stewardship is required in hospitals, including in the ED. In addition, a significant number of patients received antibiotics until the time of death, highlighting the need for improved end-of-life care with less burdensome interventions. Further education of medical staff, regular medication reviews and the use of disease severity scores or clinical pathways may address some of these issues.
